For instance, the addition of a missense mutant TP53 inhibitor APR-246 to the proteasome inhibitor Carfilzomib has been demonstrated to be active in vivo on triple-negative breast cancer models, a tumor carrying a molecular background similar to CNH endometrial carcinoma [34]. This evidence concerns the gene TP53 and triple-negative breast carcinoma.